ABSTRACT
PURPOSE: To evaluate septal perfusion and contractility in patients with left bundle branch block (LBBB). METHODS: Twenty patients were submitted to myocardial scintigraphy with Tecnecium-99m isontrile after exercise and dipyridamole infusion. The septal contractility was observed during the radionuclide ventriculography. All patients were submitted to coronariography. RESULTS: Twenty patients were studied and 17 (85%) had a normal left anterior descending (LAD) artery. Nine (53%) patients had abnormalities in septal perfusion after the exercise and 2 (12%) after dipyridamole infusion. All patients had abnormalities in septal contractility during the radionuclide ventriculography. CONCLUSION: The myocardial scintigraphy after dipyridamole infusion showed better specificity in the diagnosis of a LAD lesion. The radionuclide ventriculography was an efficient method to evaluate the septal contraction abnormalities in patients with LBBB.
Subject(s)
Bundle-Branch Block/diagnostic imaging , Coronary Disease/diagnostic imaging , Radiopharmaceuticals , Technetium Tc 99m Sestamibi , Bundle-Branch Block/complications , Coronary Disease/complications , Dipyridamole , Heart Septum/diagnostic imaging , Humans , Middle Aged , Prospective Studies , Radionuclide VentriculographyABSTRACT
Os autores apresentam um caso de feocromocitoma intratorácico demonstrado e localizado através da cintilografia com MIBG-131, e sua correlaçäo com a radiografia convencional e tomografia computadorizada
Subject(s)
Humans , Female , Adult , Adrenal Gland Neoplasms/analysis , Nuclear Medicine , Pheochromocytoma/diagnosis , BrazilABSTRACT
The effect of levamisole HCL on advanced and recurrent breast cancer was investigated cooperatively by a randomized controlled study using envelope method. Patients with advanced and recurrent breast cancer who had showed either complete response or partial response to the previous CAF therapy (cyclophosphamide 100 mg/body/day p.o. from day 1 to 14, adriamycin 30 mg/body/day i.v. on day 1 and 8, 5-FU 500 mg/body/day i.v. on day 1 and 8) were entered in this study and divided randomly into a control group and a levamisole group. No further treatment was given to patients of the control group until they fell into progressive disease. Patients of the levamisole group were given the drug at a daily dose of 150 mg for 3 consecutive days every fortnight. Fifty-nine cases were entered in this protocol, but 9 cases of them were ruled out as exclusions or dropouts. Therefore, the number of eligible cases was 31 in the levamisole group and 19 in the control group. Both the duration of remission and the survival time were significantly (p less than 0.05) prolonged in the levamisole group compared with the control group. There was no difference in side effects between these two groups.
